Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2006

Xenomics Develops Test for AML

  • Xenomics developed a test for the detection of NPM gene mutations, a recently discovered genetic marker for acute myeloid leukemia (AML). Xenomics already holds the exclusive license for the use of that marker.

    “The NPM genetic marker is critically important to physicians because it can provide a diagnostic tool to identify an especially aggressive form of AML much more rapidly and effectively than conventional techniques,” explains David Tomei, Ph.D., CEO and co-founder. “This test developed by Xenomics is capable of detecting all known NPM mutations in DNA from bone marrow or blood cells of AML patients in one reaction with high sensitivity and specificity.

    “We are now preparing to move this test into the clinical setting,” adds Dr. Tomei.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »